Abstract 1943: SHP2 inhibition as the backbone of targeted therapy combinations for the treatment of cancers driven by oncogenic mutations in the RAS pathway
Sign Up to like & getrecommendations! Published in 2020 at "Cancer Research"
DOI: 10.1158/1538-7445.am2020-1943
Abstract: Direct targeting of oncogenic mutations in the RAS pathway, such as mutant EGFR, BRAFV600E, and most recently KRASG12C, has emerged as a beneficial therapeutic strategy for patients with cancers bearing these mutations. Mutant-selective inhibitors offer… read more here.
Keywords: shp2 inhibition; selective inhibitors; oncogenic mutations; mutations ras ... See more keywords
Expression of PD-L1 in colorectal cancer that lack mutations in RAS or TP53 genes.
Sign Up to like & getrecommendations! Published in 2017 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2017.35.15_suppl.e14500
Abstract: e14500Background: PD-L1 expression as detected by immunohistochemistry (IHC) is significantly lower in colorectal cancers (CRC) when compared with lung cancer or other types of cancer. We explored if mutations in the RAS/RAF gene family, TP53… read more here.
Keywords: mutations ras; expression; cancer; expression colorectal ... See more keywords
Mutations of RAS genes in endometrial polyps
Sign Up to like & getrecommendations! Published in 2019 at "Oncology Reports"
DOI: 10.3892/or.2019.7353
Abstract: Endometrial polyps are common, yet the molecular mechanisms underlying their formation and progression remain unclear. We examined gene mutations possibly related to the pathogenesis of endometrial polyps, as well as to their clinical features. Four… read more here.
Keywords: endometrial polyps; genes endometrial; ras genes; ras mutations ... See more keywords